Cerus Corporation
$ 3.04
4.11%
29 May - close price
- Market Cap 565,041,000 USD
- Current Price $ 3.04
- High / Low $ 3.13 / 2.88
- Stock P/E N/A
- Book Value 0.34
- EPS -0.05
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.15 %
- 52 Week High 3.15
- 52 Week Low 1.15
About
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Analyst Target Price
$4.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-02 | 2025-11-06 | 2025-08-05 | 2025-05-01 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-03-05 | 2023-11-02 | 2023-08-02 |
| Reported EPS | -0.01 | -0.01 | -0.0001 | -0.03 | -0.04 | -0.01 | -0.02 | -0.03 | -0.05 | -0.01 | -0.03 | -0.06 |
| Estimated EPS | -0.04 | -0.0075 | -0.02 | -0.02 | -0.05 | -0.01 | -0.03 | -0.04 | -0.04 | -0.02 | -0.05 | -0.06 |
| Surprise | 0.03 | -0.0025 | 0.0199 | -0.01 | 0.01 | 0 | 0.01 | 0.01 | -0.01 | 0.01 | 0.02 | 0 |
| Surprise Percentage | 75% | -33.3333% | 99.5% | -50% | 20% | 0% | 33.3333% | 25% | -25% | 50% | 40% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERS
2026-05-27 15:40:38
Bradley L. Radoff, a major shareholder in Cerus Corporation, announced his intention to vote against the re-election of CEO William Greenman and Compensation Committee Chair Ann Lucena at the upcoming June 2, 2026 annual meeting. Radoff cites negative returns, significant stock dilution, and concerns over Greenman's planned transition to Executive Chair as reasons for his opposition. He argues that the company has failed to create shareholder value and maintains a problematic classified Board structure.
2026-05-25 06:09:54
Cerus Corp reported a 24% increase in product revenue for Q1 2026, driven by strong global platelet franchise and U.S. ISC business, leading to raised full-year 2026 product revenue guidance. The company secured a multi-year contract with the French National Blood Service and achieved its eighth consecutive quarter of positive non-GAAP adjusted EBITDA. However, Cerus faces logistical challenges in the Middle East and a decrease in gross margin due to inflationary pressures and tariffs.
2026-05-23 12:09:12
BTIG has upgraded Cerus Corporation (NASDAQ: CERS) to Buy from Neutral, reiterating a $4 price target. This upgrade follows strong Q1 2026 financial results, with total revenue up 23% and product revenue up 24% year-over-year. Cerus also raised its full-year product revenue guidance and outlined significant upcoming regulatory and clinical milestones.
2026-05-23 12:09:12
Cerus Corporation (NASDAQ: CERS) has been upgraded to "Buy" from "Neutral" by BTIG following its strong Q1 2026 financial results. The company reported a 23% increase in total revenue and a 24% rise in product revenue, prompting an upward revision of its full-year product revenue guidance. Cerus also anticipates several significant regulatory and clinical milestones in 2026, driven by rising demand for its INTERCEPT Fibrinogen Complex.
2026-05-21 08:10:18
Cerus Corp (CERS) stock has seen a significant rebound, attracting renewed investor interest after a challenging 2024. The blood safety company, known for its INTERCEPT Blood System, is gaining attention as a turnaround story among healthcare penny stocks. Despite historically reporting net losses, the company aims for improved profitability through sales growth and cost control, particularly as it pursues expansion into red blood cell applications.
2026-05-19 08:10:55
Cerus Corp recently reported its Q1 2026 results, highlighting revenue growth driven by increased adoption of its INTERCEPT blood safety systems, particularly for platelets in the US and Europe. The company, which specializes in pathogen reduction technologies, is aiming for profitability by focusing on recurring revenue from disposable kits and exploring collaborations with public agencies. While its core business is strong, Cerus navigates a highly regulated medical technology market with ongoing innovation and clinical data to support broader adoption.
